EUVIMEDEUVIMED entdecken
Crossref

Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections

Varsha V Nair iD, Hugh D C Smyth

Molecular Pharmaceutics · 04.09.2023 · 20 (9) · 4640-4653

DOI: 10.1021/acs.molpharmaceut.3c00395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 22.08.2023. Verfasst von Varsha V Nair und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, Texas 787…. Hauptthemen laut MEDLINE: Pneumonia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tigecycline (TIG) is a broad-spectrum antibiotic that has been approved for the treatment of a number of complicated infections, including community-acquired bacterial pneumonia. Currently it is available only as an intravenous injection that undergoes rapid chemical degradation and limits the use to in-patient scenarios. The use of TIG as an inhaled dry powder inhaler may offer a promising treatment option for patients with multidrug-resistant respiratory tract infections, such as Stenotrophomonas maltophilia (S. maltophilia). This study explores the feasibility of engineering an inhaled powder formulation of TIG that could administer relevant doses at a wide range of inhalation flow rates while maintaining stability of this labile drug. Using air-jet milling, micronized TIG had excellent aerosolization efficiency, with over 80% of the device emitted dose being within the respirable range. TIG was also readily dispersed using different inhaler devices even when tested at different pressure drops and flow rates. Additionally, micronized TIG was stable for 6 months at 25 °C/60% RH and 40 °C/75% RH. Micronized TIG maintained a low minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) of 0.8 μM and >0.5 μM, respectively in S. maltophilia cultures in vitro. These results strongly suggest that the micronization of TIG results in a stable and respirable formulation that can be delivered via the pulmonary route for the treatment of lung infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PneumoniaHumansTigecyclinePowdersAnti-Bacterial AgentsDry Powder InhalersExcipients

Stichwörter der Autor:innen

Excipient FreeJet MillingLung InfectionsPulmonary DeliveryTigecycline

Substanzen

TigecyclinePowdersAnti-Bacterial AgentsExcipients

Autor:innen und Institutionen

  • Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, Texas 78712, United States.

ORCID-Profile: Varsha V Nair

Zitieren

APA

Nair, V. V., & Smyth, H. D. C. (2023). Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections. Molecular Pharmaceutics, 20(9), 4640-4653. https://doi.org/10.1021/acs.molpharmaceut.3c00395

Vancouver

Nair VV, Smyth HDC. Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections. Molecular Pharmaceutics. 2023;20(9):4640-4653. doi:10.1021/acs.molpharmaceut.3c00395

BibTeX
@article{Nair2023,
  author = {Nair, Varsha V and Smyth, Hugh D C},
  title = {Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {9},
  pages = {4640--4653},
  doi = {10.1021/acs.molpharmaceut.3c00395}
}
Kostenlos starten →